• Donate
  • Contact
Canadian Association of Pompe
  • Home
  • About Us
    • Portraits of Pompe
    • Our Partners
    • Newsletter
  • About Pompe
    • Webinars
  • Blog
  • Links
  • Connections
Select Page
Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics

by Brad Crittenden | Dec 2, 2019 | News

This development should provide Audentes with additional resources for their gene therapy programs, including a Phase 1/2 study for Pompe disease.

Recent Posts

  • Amicus Therapeutics Has Begun the FDA Submission for Their Pompe Drug, AT-GAA
  • New Review Article Highlights Latest Developments in Pompe Disease Research
  • The Genetic Non-Discrimination Act
  • New ERT For Late-onset Pompe Disease Shows Promise
  • 2020 CAP Annual General Meeting
  • Terms
  • Privacy

Copyright © 2006 - 2021 Canadian Association of Pompe | Developed by PacificByte

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok